We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for avalglucosidase alfa (Sanofi-Aventis Australia Pty Ltd)
Active ingredients
avalglucosidase alfa
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Powder for injection
Indication
Avalglucosidase alfa is intended for long-term enzyme replacement therapy (ERT) for the treatment of patients with Pompe disease (acid α-glucosidase deficiency)
Therapeutic area
Inherited metabolic disorders